Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle.
Cancer cachexia is a syndrome of weight loss that results from the selective depletion of skeletal muscle mass and contributes significantly to cancer morbidity and mortality. The driver of skeletal muscle atrophy in cancer cachexia is systemic inflammation arising from both the cancer and cancer tr...
Main Authors: | Theodore P Braun, Marek Szumowski, Peter R Levasseur, Aaron J Grossberg, XinXia Zhu, Anupriya Agarwal, Daniel L Marks |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4177815?pdf=render |
Similar Items
-
The Regulation of Muscle Mass by Endogenous Glucocorticoids
by: Daniel L Marks, et al.
Published: (2015-02-01) -
The Positive Impact of Vitamin D on Glucocorticoid-Dependent Skeletal Muscle Atrophy
by: Mateusz Jakub Karnia, et al.
Published: (2021-03-01) -
Nutrients against Glucocorticoid-Induced Muscle Atrophy
by: Min-Kyeong Lee, et al.
Published: (2022-02-01) -
Antagonizing urotensin receptor is a novel therapeutic strategy for glucocorticoid‐induced skeletal muscle atrophy
by: Lin Yin, et al.
Published: (2022-05-01) -
Inflammation: Roles in Skeletal Muscle Atrophy
by: Yanan Ji, et al.
Published: (2022-08-01)